Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial results.
about
Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.Have physiologically-based pharmacokinetic models delivered?D optimal designs for three Poisson dose-response models.Effects of Grapefruit and Pomegranate Juices on the Pharmacokinetic Properties of Dapoxetine and Midazolam in Healthy Subjects.Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model.
P2860
Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial results.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Drug-drug interaction predicti ...... art 2: clinical trial results.
@en
Drug-drug interaction predicti ...... art 2: clinical trial results.
@nl
type
label
Drug-drug interaction predicti ...... art 2: clinical trial results.
@en
Drug-drug interaction predicti ...... art 2: clinical trial results.
@nl
prefLabel
Drug-drug interaction predicti ...... art 2: clinical trial results.
@en
Drug-drug interaction predicti ...... art 2: clinical trial results.
@nl
P2093
P2860
P1476
Drug-drug interaction predicti ...... art 2: clinical trial results.
@en
P2093
Fanny Cazade
France Mentré
François Bouzom
Kayode Ogungbenro
Leon Aarons
Marylore Chenel
P2860
P2888
P304
P356
10.1007/S10928-008-9105-5
P577
2008-12-01T00:00:00Z